SEC recommends Phase 1 trials of Reliance’s Covid vaccine candidate
India Today
The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance Life Sciences' two-dose Covid-19 vaccine candidate.
The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance’s recombinant vaccine candidate. Earlier, Mukesh Ambani-owned Reliance Life Sciences had sought approval for the Phase I trial of its proposed two-dose Covid-19 vaccine. The company received the approval during the SEC meeting on Friday.More Related News